No nothing specific mentioned on Peer Reviews, just ongoing analysis and usual due process which in Biotron terms could be within next decade but who cares anyway. All market cares about now is $$ as we are approaching zero bank balance. We don't want to direct investors towards the frazzled trainwreck CEO in webinar anyhow, an utterly abysmal performance, deflection and blame game in all directions other than her own performance over 20 years as CEO.
